In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Javed Butler
Speaker
Javed Butler
Javed Butler Javed Butler

The University of Mississippi Medical Center, Jackson (United States of America)

Speciality : Acute Heart Failure

Javed Butler, MD, MPH, MBA, is the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi. He received his medical degree from the Aga Khan University, residency training at Yale University, cardiology and heart failure and transplant fellowships at Vanderbilt University, and cardiac imaging fellowship at the Massachusetts General Hospital. He has completed MPH from Harvard and MBA from Emory. Dr. Butler is board certified in Cardiology and in Heart failure and transplant medicine. He had received Simon Dack Award from ACC and Time, Feeling, and Focus Award from AHA. He has authored more than 600 peer-reviewed publications.

52 presentations from this speaker

Discussion.

Event : ESC Congress 2020

  • Session : Changing the outlook for a chronic heart failure patient: Optimising RAASi treatment through long-term potassium control
  • Speaker : P Van Der Meer (Groningen,NL), CS Lam (Singapore,SG), P Ponikowski (Wroclaw,PL), J Butler (Atlanta,US)
  • Organised by PACE-CME, supported by Vifor Pharma Group in the form of an educational grant

How may novel potassium binders help improve the management of chronic heart failure?

Event : ESC Congress 2020

  • Session : Changing the outlook for a chronic heart failure patient: Optimising RAASi treatment through long-term potassium control
  • Speaker : J Butler (Atlanta,US)
  • Organised by PACE-CME, supported by Vifor Pharma Group in the form of an educational grant

Improving quality of life in heart failure patients – latest evidence on the role of IV iron.

Event : ESC Congress 2020

  • Session : The changing landscape of iron deficiency in heart failure
  • Speaker : J Butler (Atlanta,US), EA Jankowska (Wroclaw,PL)
  • Organised by Charité, supported by Vifor Pharma in the form of an educational grant

Interactive panel discussion.

Event : ESC Congress 2020

  • Session : The changing landscape of iron deficiency in heart failure
  • Speaker : S Anker (Berlin,DE), J Butler (Atlanta,US), A Coats (Warwickshire,GB), EA Jankowska (Wroclaw,PL), P Ponikowski (Wroclaw,PL), P Van Der Meer (Groningen,NL), S Zieroth (Winnipeg,CA)
  • Organised by Charité, supported by Vifor Pharma in the form of an educational grant

Introduction.

Event : ESC Congress 2020

  • Session : New evidence on sodium-glucose transport protein 2 inhibitors therapy in heart failure patients
  • Speaker : J Butler (Atlanta,US)
  • Organised by Charité IME, supported by Boehringer Ingelheim & Eli Lilly and Company Alliance in the form of an educational grant

Live panel discussion and close.

Event : ESC Congress 2020

  • Session : Time to Take the Lead – Practical Utilization of SGLT2 Inhibitors
  • Speaker : S Zieroth (Winnipeg,CA), J Butler (Atlanta,US), S Anker (Berlin,DE)
  • Organised by Radcliffe Medical Education, supported by Boehringer Ingelheim & Eli Lilly and Company Alliance in the form of an educational grant

Panel discussion

Event : ESC Congress 2020

  • Session : New evidence on sodium-glucose transport protein 2 inhibitors therapy in heart failure patients
  • Speaker : G Filippatos (Athens,GR), J Butler (Atlanta,US), M Packer (Dallas,US), S Anker (Berlin,DE), F Zannad (Vandoeuvre,FR)
  • Organised by Charité IME, supported by Boehringer Ingelheim & Eli Lilly and Company Alliance in the form of an educational grant

Panel discussion and live Q&A.

Event : ESC Congress 2020

  • Session : Therapeutic advances in HFrEF patients who have had a previous worsening HF event
  • Speaker : CS Lam (Singapore,SG), B Pieske (Berlin,DE), J Ezekowitz (Edmonton,CA), J Butler (Atlanta,US)
  • Sponsored by Bayer AG

Putting the VICTORIA trial into perspective with contemporary HFrEF clinical trials.

Event : ESC Congress 2020

  • Session : Therapeutic advances in HFrEF patients who have had a previous worsening HF event
  • Speaker : J Butler (Atlanta,US)
  • Sponsored by Bayer AG

Session Introduction.

Event : ESC Congress 2020

  • Session : Time to Take the Lead – Practical Utilization of SGLT2 Inhibitors
  • Speaker : J Butler (Atlanta,US)
  • Organised by Radcliffe Medical Education, supported by Boehringer Ingelheim & Eli Lilly and Company Alliance in the form of an educational grant

SGLT2 inhibition: Making waves in the heart failure landscape.

Event : HFA Discoveries 2020

  • Session : SGLT2 inhibition: Making waves in the heart failure landscape
  • Speaker : CS Lam (Singapore,SG), J Butler (Atlanta,US), M Petrie (Glasgow,GB), GMC Rosano (London,GB)
  • Organised by CHANGE IME in partnership with Leicester Diabetes Centre

SGLT2i are Cardiovascular Drugs

Event : ESC Congress 2020

  • Session : Time to Take the Lead – Practical Utilization of SGLT2 Inhibitors
  • Speaker : J Butler (Atlanta,US)
  • Organised by Radcliffe Medical Education, supported by Boehringer Ingelheim & Eli Lilly and Company Alliance in the form of an educational grant

Sharing best practice in hyperkalaemia management.

Event : ESC Congress 2020

  • Session : Rethinking and rechallenging RAASi therapy in patients with hyperkalaemia
  • Speaker : A Voors (Groningen,NL), J Butler (Atlanta,US), P McCullough (Texas,US), C Gavina (Matosinhos,PT)
  • Organised by ChangeIME, supported by AstraZeneca in the form of an educational grant

Welcome and introduction.

Event : ESC Congress 2020

  • Session : Rethinking and rechallenging RAASi therapy in patients with hyperkalaemia
  • Speaker : J Butler (Atlanta,US), A Voors (Groningen,NL)
  • Organised by ChangeIME, supported by AstraZeneca in the form of an educational grant

Discussion - New therapeutic options in the treatment of mitral regurgitation: practical considerations.

Event : Heart Failure 2019

  • Session : New therapeutic options in the treatment of mitral regurgitation: practical considerations
  • Speaker : R Von Bardeleben (Mainz,DE), J Butler (Atlanta,US), M Boehm (Homburg,DE)
  • Organised by Charité Berlin, supported with an educational grant from Edwards

Introduction and welcome - The evolving role of cardiologists: can we help decrease the cardiovascular event burden in patients with type 2 diabetes?

Event : Heart Failure 2019

  • Session : The evolving role of cardiologists: can we help decrease the cardiovascular event burden in patients with type 2 diabetes?
  • Speaker : J Butler (Atlanta,US)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Alliance

Obesity and diabetes: impact on heart failure outcomes.

Event : Heart Failure 2019

  • Session : A crosstalk between diabetes and heart failure
  • Speaker : J Butler (Atlanta,US)

Ongoing clinical trials in HFPEF.

Event : Heart Failure 2019

  • Session : HFpEF: current diagnosis and management
  • Speaker : J Butler (Atlanta,US)

Open questions and answers - The evolving role of cardiologists: can we help decrease the cardiovascular event burden in patients with type 2 diabetes?

Event : Heart Failure 2019

  • Session : The evolving role of cardiologists: can we help decrease the cardiovascular event burden in patients with type 2 diabetes?
  • Speaker : J Butler (Atlanta,US), R Fontes Carvalho (Porto,PT)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Alliance

Optimising treatment for patients in the vulnerable phase.

Event : Heart Failure 2019

  • Session : Treatment choices to optimise benefits for heart failure patients
  • Speaker : J Butler (Atlanta,US)
  • Sponsored by Novartis

Panel discussion - Making critical choices for patients at the right time.

Event : Heart Failure 2019

  • Session : Making critical choices for patients at the right time – Join the discussion
  • Speaker : F Ruschitzka (Zurich,CH), JJV McMurray (Glasgow,GB), M Senni (Bergamo,IT), J Butler (Atlanta,US)
  • Sponsored by Novartis

Panel discussion - Treatment choices to optimise benefits for heart failure patients.

Event : Heart Failure 2019

  • Session : Treatment choices to optimise benefits for heart failure patients
  • Speaker : F Ruschitzka (Zurich,CH), JJV McMurray (Glasgow,GB), M Senni (Bergamo,IT), J Butler (Atlanta,US)
  • Sponsored by Novartis

Panel discussion and close - Management of hyperkalaemia in patients with heart failure – Overcoming barriers to optimal renin-angiotensin-aldosterone system inhibitor therapy.

Event : Heart Failure 2019

  • Session : Management of hyperkalaemia in patients with heart failure – Overcoming barriers to optimal renin-angiotensin-aldosterone system inhibitor therapy
  • Speaker : J Butler (Atlanta,US)
  • Organised by MedEd Global Solutions & University of Lorraine, supported with an educational grant from Vifor Pharma

sGC-cGMP: currently an untapped pathway in HFrEF

Event : ESC Congress 2019

  • Session : New approach for worsening chronic heart failure
  • Speaker : J Butler (Atlanta,US)
  • Sponsored by Bayer AG

SGLT2 inhibitors: what is the evidence so far?

Event : Heart Failure 2019

  • Session : Know it by heart – New opportunities for cardiologists in the Sodium-Glucose-Co-Transporter 2 (SGLT2) inhibitor era
  • Speaker : J Butler (Atlanta,US)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Alliance

Treatment of type 2 diabetes with/without heart failure: pending results from ongoing trials.

Event : Heart Failure 2019

  • Session : Focus on diabetes in heart failure
  • Speaker : J Butler (Atlanta,US)

Welcome and introduction - New therapeutic options in the treatment of mitral regurgitation: practical considerations.

Event : Heart Failure 2019

  • Session : New therapeutic options in the treatment of mitral regurgitation: practical considerations
  • Speaker : J Butler (Atlanta,US), M Boehm (Homburg,DE)
  • Organised by Charité Berlin, supported with an educational grant from Edwards

Clinical case discussion.

Event : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors therapy
  • Speaker : J Comin-Colet (Hospitalet De Llobregat,ES), J Butler (Atlanta,US)
  • Sponsored by Vifor Pharma

Design and rationale of the EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure (EMPEROR-Preserved)

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : J Butler (Atlanta,US)

Diagnosing residual congestion before discharging heart failure patients

Event : ESC Congress 2018

  • Session : Expert Advice - How to prevent readmissions in patients with acute heart failure
  • Speaker : J Butler (Atlanta,US)

Empagliflozin improves renal outcomes in patients with or without heart failure at baseline - insights from the EMPA-REG OUTCOME trial

Event : Heart Failure 2018

  • Session : Patient management - From oral treatment to transplant
  • Speaker : J Butler (Atlanta,US)

Open Q&A

Event : ESC Congress 2018

  • Session : Reducing premature cardiovascular mortality in patients with type 2 diabetes: best practice in cardiology
  • Speaker : S Anker (Berlin,DE), J Butler (Atlanta,US)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Panel discussion and close - Hyperkalaemia and iron deficiency: time for a paradigm change.

Event : ESC Congress 2018

  • Session : Co-morbidities in chronic heart failure – time for paradigm shifts in the management of hyperkalaemia and iron deficiency
  • Speaker : J Butler (Atlanta,US), G Filippatos (Athens,GR), S Anker (Berlin,DE), P Van Der Meer (Groningen,NL), I Pina (Detroit,US)
  • Organised by Charité supported with an educational grant from Vifor

Panel discussion.

Event : Heart Failure 2018

  • Session : Dilemma in cardio-renal patients: hyperkalaemia vs renin-angiotensin-aldosterone system inhibitors?
  • Speaker : J Butler (Atlanta,US)
  • Sponsored by Vifor Pharma

Potassium high, potassium low – Why bother?

Event : Heart Failure 2018

  • Session : Potassium - Friend or foe?
  • Speaker : J Butler (Atlanta,US)

Reducing premature cardiovascular mortality in patients with type 2 diabetes and established cardiovascular disease

Event : ESC Congress 2018

  • Session : Reducing premature cardiovascular mortality in patients with type 2 diabetes: best practice in cardiology
  • Speaker : J Butler (Atlanta,US)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Role of biomarkers in cardiovascular clinical trials.

Event : ESC Congress 2018

  • Session : Biomarkers in cardiology
  • Speaker : J Butler (Atlanta,US)
  • Sponsored by Roche

Brain.

Event : Heart Failure 2017

  • Session : Organ dysfunction in acute heart failure
  • Speaker : J Butler (Atlanta,US)

Changing the treatment paradigm of hyperkalemia management to enable and optimize RAASi therapy.

Event : Heart Failure 2017

  • Session : Enabling and optimizing Renin-Angiotensin-Aldosterone-System inhibitors (RAASi) therapy in cardio-renal patients by controlling potassium levels
  • Speaker : J Butler (Atlanta,US)
  • Sponsored by Vifor Pharma / Vifor Fresenius Medical Care Renal Pharma

HNO Donors.

Event : Heart Failure 2017

  • Session : Novel drugs in acute heart failure: hurdles, hype and hope
  • Speaker : J Butler (Atlanta,US)

Lighting the way: a new path to manage hyperkalaemia.

Event : ESC Congress 2017

  • Session : Lighting the way: a new path to manage hyperkalaemia (EBAC Accredited)
  • Speaker : J Butler (Atlanta,US)
  • Sponsored by AstraZeneca

Cardioxyl

Event : ESC Congress 2016

  • Session : New drugs in acute heart failure
  • Speaker : J Butler (Atlanta,US)

Cardioxyl.

Event : Heart Failure 2016

  • Session : Drugs in the pipeline for acute heart failure
  • Speaker : J Butler (Atlanta,US)

New pathways and therapeutic targets to treat chronic heart failure.

Event : Heart Failure 2016

  • Session : Targeting cardiac and non-cardiac comorbidities in heart failure
  • Speaker : J Butler (Atlanta,US)
  • Sponsored by Bayer

State of the art in cardio-oncology.

Event : ESC Congress 2016

  • Session : Cardiac problems and related therapies for cancer patients
  • Speaker : J Butler (Atlanta,US)

Cardiorenal syndrome.

Event : Heart Failure 2015

  • Session : Clinical fundamentals of multiple organ dysfunction
  • Speaker : J Butler (Atlanta,US)

Unmet medical needs in HFrEF and possible ways to address them.

Event : Heart Failure 2015

  • Session : What's hot in heart failure: defining unmet medical needs and innovative targets for therapy
  • Speaker : J Butler (Atlanta,US)
  • Sponsored by Bayer Healthcare

Who should be involved and who is responsible?

Event : ESC Congress 2014

  • Session : How to set up a heart failure service?
  • Speaker : J Butler (Atlanta,US)

Worsening renal function.

Event : ESC Congress 2013

  • Session : Challenges in decompensated heart failure
  • Speaker : J Butler (Atlanta,US)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are